China · Delayed Price · Currency is CNY CTI BioPharma Statistics
Total Valuation
Luyan Pharma has a market cap or net worth of CNY 3.37 billion. The enterprise value is 8.08 billion.
| Market Cap | 3.37B |
| Enterprise Value | 8.08B |
Important Dates
The next estimated earnings date is Tuesday, August 26, 2025.
| Earnings Date | Aug 26, 2025 |
| Ex-Dividend Date | Jul 10, 2025 |
Share Statistics
Luyan Pharma has 388.52 million shares outstanding. The number of shares has increased by 1.39% in one year.
| Current Share Class | 388.52M |
| Shares Outstanding | 388.52M |
| Shares Change (YoY) | +1.39% |
| Shares Change (QoQ) | +3.27% |
| Owned by Insiders (%) | 3.68% |
| Owned by Institutions (%) | 3.01% |
| Float | 231.73M |
Valuation Ratios
The trailing PE ratio is 10.22.
| PE Ratio | 10.22 |
| Forward PE | n/a |
| PS Ratio | 0.16 |
| PB Ratio | 1.03 |
| P/TBV Ratio | 1.30 |
| P/FCF Ratio | 11.33 |
| P/OCF Ratio | 5.60 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.10, with an EV/FCF ratio of 27.12.
| EV / Earnings | 24.24 |
| EV / Sales | 0.39 |
| EV / EBITDA | 10.10 |
| EV / EBIT | 12.08 |
| EV / FCF | 27.12 |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 1.57.
| Current Ratio | 1.15 |
| Quick Ratio | 0.80 |
| Debt / Equity | 1.57 |
| Debt / EBITDA | 6.42 |
| Debt / FCF | 17.24 |
| Interest Coverage | 3.28 |
Financial Efficiency
Return on equity (ROE) is 10.59% and return on invested capital (ROIC) is 5.07%.
| Return on Equity (ROE) | 10.59% |
| Return on Assets (ROA) | 3.39% |
| Return on Invested Capital (ROIC) | 5.07% |
| Return on Capital Employed (ROCE) | 16.34% |
| Revenue Per Employee | 3.66M |
| Profits Per Employee | 59,477 |
| Employee Count | 5,602 |
| Asset Turnover | 1.66 |
| Inventory Turnover | 7.38 |
Taxes
In the past 12 months, Luyan Pharma has paid 106.35 million in taxes.
| Income Tax | 106.35M |
| Effective Tax Rate | 24.15% |
Stock Price Statistics
The stock price has increased by +16.51% in the last 52 weeks. The beta is 0.43, so Luyan Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | +16.51% |
| 50-Day Moving Average | 8.53 |
| 200-Day Moving Average | 8.41 |
| Relative Strength Index (RSI) | 55.44 |
| Average Volume (20 Days) | 4,898,850 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Luyan Pharma had revenue of CNY 20.51 billion and earned 333.19 million in profits. Earnings per share was 0.85.
| Revenue | 20.51B |
| Gross Profit | 1.51B |
| Operating Income | 668.69M |
| Pretax Income | 440.28M |
| Net Income | 333.19M |
| EBITDA | 737.22M |
| EBIT | 668.69M |
| Earnings Per Share (EPS) | 0.85 |
Balance Sheet
The company has 457.88 million in cash and 5.13 billion in debt, giving a net cash position of -4.67 billion or -12.03 per share.
| Cash & Cash Equivalents | 457.88M |
| Total Debt | 5.13B |
| Net Cash | -4.67B |
| Net Cash Per Share | -12.03 |
| Equity (Book Value) | 3.26B |
| Book Value Per Share | 8.32 |
| Working Capital | 1.30B |
Cash Flow
In the last 12 months, operating cash flow was 602.29 million and capital expenditures -304.55 million, giving a free cash flow of 297.74 million.
| Operating Cash Flow | 602.29M |
| Capital Expenditures | -304.55M |
| Free Cash Flow | 297.74M |
| FCF Per Share | 0.77 |
Margins
Gross margin is 7.35%, with operating and profit margins of 3.26% and 1.62%.
| Gross Margin | 7.35% |
| Operating Margin | 3.26% |
| Pretax Margin | 2.15% |
| Profit Margin | 1.62% |
| EBITDA Margin | 3.59% |
| EBIT Margin | 3.26% |
| FCF Margin | 1.45% |
Dividends & Yields
This stock pays an annual dividend of 0.35, which amounts to a dividend yield of 4.10%.
| Dividend Per Share | 0.35 |
| Dividend Yield | 4.10% |
| Dividend Growth (YoY) | 16.67% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 97.78% |
| Buyback Yield | -1.39% |
| Shareholder Yield | 2.71% |
| Earnings Yield | 9.88% |
| FCF Yield | 8.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 29, 2019. It was a forward split with a ratio of 1.7.
| Last Split Date | May 29, 2019 |
| Split Type | Forward |
| Split Ratio | 1.7 |
Scores
Luyan Pharma has an Altman Z-Score of 2.37 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.37 |
| Piotroski F-Score | 4 |